Osimertinib's Benefits in NSCLC Can Extend Beyond First Line
Patients with EGFR-mutated NSCLC who progress on first-line osimertinib live longer without disease worsening when the drug is maintained alongside chemotherapy second line.
Medscape Medical News
source https://www.medscape.com/viewarticle/osimertinibs-benefits-nsclc-can-extend-beyond-first-line-2025a1000nlc?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/osimertinibs-benefits-nsclc-can-extend-beyond-first-line-2025a1000nlc?src=rss
Comments
Post a Comment